2025
Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer
Sridharan A, Dotan E, Dorta M, Vemula N, Handorf E, Deng M, Renning A, Sorice K, Laderman L, Whittington K, Cukierman E, Astsaturov I, Vijayvergia N, Meyer J, Reddy S, Lynch S. Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. Journal Of Gastrointestinal Cancer 2025, 56: 67. PMID: 39954184, PMCID: PMC11829832, DOI: 10.1007/s12029-025-01188-x.Peer-Reviewed Original ResearchConceptsSocioeconomic statusHazard ratioConfidence intervalsSocioeconomic status populationsCancer CenterComprehensive cancer centerDiagnosis to first treatmentPatient-level variablesAcademic cancer centerCox proportional hazards regressionReceipt of chemotherapyMultivariable Cox proportional hazards regressionProportional hazards regressionT2TCancer disparitiesNeighborhood deprivationRace/ethnic disparitiesDisparity indicatorsRacial/ethnic differencesHospital settingEffects of racePatient raceDiagnosis to treatmentUS CensusMetastatic PDACThe association between clinical trial participation, drug costs, and performance in the Oncology Care Model
Canavan M, Westvold S, Csik V, Franks J, Rocque G, Gross C, Adelson K. The association between clinical trial participation, drug costs, and performance in the Oncology Care Model. Journal Of The National Cancer Institute 2025, djaf008. PMID: 39842859, DOI: 10.1093/jnci/djaf008.Peer-Reviewed Original ResearchOncology Care ModelCare modelValue-based payment programsMedicare alternative payment modelsAlternative payment modelsRandom-effects meta-analysisImpact of clinical trialsClinical trial participationCT episodesEffects meta-analysisAcademic oncology practicesImprove careClinical trialsPatient complexityPayment modelsPayment programsMedicare costsTrial participantsOncology practiceCancer CenterMeta-analysisMedicareDrug costsParticipantsOncologyGlucarpidase for Treatment of High-Dose Methotrexate Toxicity
Gupta S, Kaunfer S, Chen K, Dias J, Vijayan A, Rajasekaran A, Prosek J, Truong H, Wood A, Bassil C, Renaghan A, Shah C, Zhang J, Glezerman I, Carlos C, Kelly K, Passero C, Drappatz J, Abudayyeh A, Shin D, Sperati C, Yelvington B, Kanduri S, Neyra J, Edmonston D, Shirali A, Bansal A, Geara A, Mithani Z, Ziolkowski S, Rashidi A, Jakubowski J, Pujari A, Bond D, Dotson E, Wall S, Patton J, Barreto J, Herrmann S, Sheikh M, Baz R, Lee J, Lucchesi N, Kolman M, Rasheed M, Afzal A, Kang D, Mahesh A, Hsu R, Nicolaysen A, Tefera K, Schretlen C, Miller R, Velez J, Flannery A, Aklilu A, Anand S, Chandrasekhara S, Donley V, Patel A, Ni J, Krishnamurthy S, Ali R, Yilmam O, Wells S, Ortega J, Green-Lingren O, Leaf R, Sise M, Nayak L, LaCasce A, Leung N, Leaf D. Glucarpidase for Treatment of High-Dose Methotrexate Toxicity. Blood 2025 PMID: 39760780, DOI: 10.1182/blood.2024026211.Peer-Reviewed Original ResearchAcute kidney injuryHigh-dose methotrexate toxicityKidney recoveryPatients treated with glucarpidaseRates of acute kidney injuryDay 7Time to deathHigh-dose methotrexateCox regression modelsGlucarpidase administrationDialysis-dependentMethotrexate toxicityMethotrexate initiationKidney injuryClinical dataGlucarpidaseCancer CenterNeutropeniaEnd pointsMethotrexatePatientsHospital dischargeOutcomesTarget trial emulation frameworkDays
2024
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.
Blanter J, Van Hyfte G, Ahmad M, Xu S, Hapanowicz O, Fazilov G, Lu A, Lucas N, Wu K, Shelton G, DeMerchant M, Lachowicz M, Kier M, Werner M, Eder J, Galsky M, Marron T, Smith C, LoRusso P, Hofstatter E, Doroshow D. Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials. JCO Oncology Practice 2024, op2400293. PMID: 39661920, DOI: 10.1200/op.24.00293.Peer-Reviewed Original ResearchEarly-phase clinical trialsSolid tumorsClinical trialsAssociated with higher FTFinancial toxicityBarriers to clinical trial enrollmentAdvanced solid malignanciesAdvanced solid tumorsInverse association with ageBaseline to 2 monthsYale Cancer CenterCOST scoreClinical trial enrollmentProspective survey studySolid malignanciesNo significant differenceBaseline FTTime of consentNovel therapiesPrimary outcomeCancer CenterSurvey 1Trial enrollmentPatientsEarly-phasePalliative Care and End-of-Life Care in Metastatic Pancreatic Cancer
O’Brien J, Halsey B, Connors M, Deng M, Handorf E, Berardi G, Lynch S, Sorice K, Reddy S, Meyer J, Bauman J, Dotan E. Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer. Journal Of Palliative Medicine 2024, 28: 217-223. PMID: 39636708, DOI: 10.1089/jpm.2024.0313.Peer-Reviewed Original ResearchEnd of lifeAggressive EOL carePalliative careDay of deathEOL carePC consultationIntegration of palliative careEnd of life careEnd-of-life careAssociated with worse qualityHealth care resourcesMetastatic pancreatic cancerQuality of lifePC teamAggressive careCare resourcesHospiceAverage length of timeTertiary cancer centerCareWorse qualityAverage timeCancer CenterBenefit patientsPancreatic cancerUpdate on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum
Cheema P, Wheatley-Price P, Cecchini M, Ellis P, Louie A, Moore S, Sheffield B, Spicer J, Villeneuve P, Leighl N. Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum. Current Oncology 2024, 31: 6979-6999. PMID: 39590145, PMCID: PMC11592966, DOI: 10.3390/curroncol31110514.Peer-Reviewed Original ResearchNon-small cell lung cancerEarly-stage non-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerLung cancerManagement of early-stage non-small cell lung cancerPre-meeting surveyTreatment approachesReview practice patternsAdjuvant settingCheckpoint inhibitorsRadiation therapyOntario cancer centersTargeted therapySurgical considerationsTreatment algorithmReview recent dataClinical dataBiomarker testingCancer CenterTherapeutic strategiesPractice patternsCancerTherapyPatientsBarriers to Recruitment and Retention Among Underrepresented Populations in Cancer Clinical Trials: A Qualitative Study of the Perspectives of Clinical Trial Research Coordinating Staff at a Cancer Center
Yousafi S, Rangachari P, Holland M. Barriers to Recruitment and Retention Among Underrepresented Populations in Cancer Clinical Trials: A Qualitative Study of the Perspectives of Clinical Trial Research Coordinating Staff at a Cancer Center. Journal Of Healthcare Leadership 2024, 16: 427-441. PMID: 39502080, PMCID: PMC11537200, DOI: 10.2147/jhl.s488426.Peer-Reviewed Original ResearchCancer clinical trialsCancer CenterCoordination staffProvision of high-quality healthcareHigh-quality healthcareNon-patient-facing staffAcademic cancer centerEvidence-based guidelinesSemi-structured interviewsLearning collaborativeStaff shortagesLack of resourcesStaff interviewsExamined barriersGeneralizability of findingsThematic analysisQualitative studyParticipant diversityCharacteristics of clinical trialsClinical trialsInadequate systemsStaffParticipation incentivesEquitable representationInterview dataUptake of Aspirin Chemoprevention in Patients With Lynch Syndrome
Singhal S, Riggs E, Ruth K, Chavez-Salas J, Chertock Y, Daly M, Hall M. Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome. JCO Precision Oncology 2024, 8: e2400562. PMID: 39546469, PMCID: PMC11573245, DOI: 10.1200/po-24-00562.Peer-Reviewed Original ResearchConceptsLynch syndromeLifetime risk of colorectal cancerColorectal cancerRisk of colorectal cancerCancer prevention optionsFactors associated with useNonsteroidal anti-inflammatory drugsDisease-related factorsChemoprevention uptakeScreening behaviorAspirin chemopreventionRelative risk reductionResearch invitationsPatients' perceptionsLifetime riskAdvocacy websitesASA/NSAID useElectronic surveyFox Chase Cancer CenterPrevention optionsCancer CenterRisk reductionMultivariate modelChemopreventive benefitsParticipantsFactors influencing timely diagnosis in neurolymphomatosis
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Traub B, Galluzzo D, Huttner A, Fulbright R, Baehring J, Kaulen L. Factors influencing timely diagnosis in neurolymphomatosis. Journal Of Neuro-Oncology 2024, 170: 309-317. PMID: 39115616, DOI: 10.1007/s11060-024-04792-2.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemDiagnostic intervalNon-Hodgkin lymphoma diagnosisSymptom onset to diagnosisCerebrospinal fluid examinationYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyRare entityMedian intervalFluid examinationQuality control databaseDelayed diagnosisPrimary diseaseUnivariate analysisConventional CTDisease sitesNeurolymphomatosisNeuro-oncologyCancer CenterSecondary diseaseImaging modalitiesNeuroimaging findingsDiagnosisAdjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatientsUsing an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.
Corvese L, Weiss C, Huie S, Zhou B, Deng Y, Gong G, Kunz P, Fischbach N. Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials. Journal Of Clinical Oncology 2024, 42: e13586-e13586. DOI: 10.1200/jco.2024.42.16_suppl.e13586.Peer-Reviewed Original ResearchClinical trialsCancer clinical trialsTrial enrollmentPercentage of patientsYale Cancer CenterClinical trial enrollmentLimitations of clinical trialsTreating providersEnrolling patientsCancer CenterUnique patientsBreast programPatientsPatient-matchedEnrollment ratesStudy-related activitiesScreening toolTrial participantsTrialsCancerOffice staffClinicEnrollmentLanguage barriersNon-EnglishThe NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers.
Roof S, Hanna G, Rettig E, Routman D, Holsinger F, Kalman N, Bhatia A, Patel M, Jabalee J, Yom S, Baliga S, Raben A, Sims J, Kaczmar J, Bhayani M, Berger B, Del Vecchio Fitz C. The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers. Journal Of Clinical Oncology 2024, 42: e15045-e15045. DOI: 10.1200/jco.2024.42.16_suppl.e15045.Peer-Reviewed Original ResearchHPV-driven cancersHPV-related cancersHuman papillomavirusClinical dataHead and neckClinical outcome dataBlood-based assayPrecision cancer medicineClinical careRoutine clinical careDNA scoreUterine cervixAcademic medical facilityImprove patient outcomesAnal canalClinicopathological featuresEligible subjectsU.S. cancer centersBlood testsOncogenic driversCancer CenterTherapeutic approachesTumor biomarkersPatientsCancer medicineAcupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer
Cohen L, Danhauer S, Garcia M, Dressler E, Rosenthal D, Chambers M, Cusimano A, Brown W, Ochoa J, Yang P, Chiang J, Gordon O, Crutcher R, Kim J, Russin M, Lukenbill J, Porosnicu M, Yost K, Weaver K, Lesser G. Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer. JAMA Network Open 2024, 7: e2410421. PMID: 38739392, PMCID: PMC11091764, DOI: 10.1001/jamanetworkopen.2024.10421.Peer-Reviewed Original ResearchConceptsSham acupunctureTrue acupunctureTreating radiation-induced xerostomiaHead and neck cancerFunctional Assessment of Cancer Therapy-General scoresRadiation-induced xerostomiaBenefits of acupunctureQuestionnaire scoresCommunity-based cancer centerNeck cancerPatient-reported outcomesRisk of biasQuality of lifeTreated 2 timesAcupuncture studiesGroup differencesStatistically significant group differencesBetween-group differencesAcupunctureXerostomia questionnaire scoreMain OutcomesSignificant group differencesFunctional assessmentStudy armsCancer CenterA retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
McNally G, Aossey C, Wiczer T, Sinnott L, Lustberg M, Baiocchi R, Lustberg M. A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter? Leukemia & Lymphoma 2024, 65: 1110-1116. PMID: 38648546, DOI: 10.1080/10428194.2024.2340051.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyIncidence of chemotherapy-induced peripheral neuropathyHIV statusPeripheral neuropathyHIV-associated non-Hodgkin's lymphomaCohort studyDose-adjusted EPOCHNon-Hodgkin's lymphomaLong-term patient outcomesRetrospective cohort studyNon-HodgkinComprehensive cancer centerCancer CenterHIVPatientsNeuropathyPatient outcomesPropensity scoreLymphomaAdverse effectsIncidenceStatusRegimenVincristineImplementation, enrollment, and engagement in an opt‐out telehealth pharmacist‐assisted tobacco treatment program for patients seen in oncology outpatient clinics
Cummings K, Toll B, Talbot V, Roberson A, Wilson D, Dunlap M, Ware E, Palmer A, Bliss A, Anokye V, Warren G. Implementation, enrollment, and engagement in an opt‐out telehealth pharmacist‐assisted tobacco treatment program for patients seen in oncology outpatient clinics. Cancer 2024, 130: 2482-2492. PMID: 38546445, PMCID: PMC11214603, DOI: 10.1002/cncr.35291.Peer-Reviewed Original ResearchTobacco treatment programOncology outpatient clinicQuit ratesDelivering smoking cessation treatmentSelf-reported quit ratesOutpatient clinicSmoking cessation counselingHollings Cancer CenterFollow-up surveyNicotine replacement medicationsTreatment programsSmoking cessation treatmentCessation counselingOncology clinicVisit clinicsCessation treatmentSmoking statusTelephone surveyCancer CenterReplacement medicationsRandom sampleAdult patientsFollow-upSmokingPatientsA Novel Approach for Conducting a Catchment Area Analysis of Breast Cancer by Age and Stage for a Community Cancer Center.
Siegel S, Zhang Y, Lynch S, Rowland J, Curriero F. A Novel Approach for Conducting a Catchment Area Analysis of Breast Cancer by Age and Stage for a Community Cancer Center. Cancer Epidemiology Biomarkers & Prevention 2024, 33: 646-653. PMID: 38451180, PMCID: PMC11062816, DOI: 10.1158/1055-9965.epi-23-1125.Peer-Reviewed Original ResearchRacial disparitiesCancer center catchment areasU.S. Preventive Services Task ForceBreast cancerPreventive Services Task ForceBlack womenCancer registry dataCenter catchment areasStandardized incidence ratioCommunity cancer centerInitial breast cancerBurden of BCCatchment areaInvasive BCBC mortalityIncidence ratiosYoung Black womenIdentified geographic areasCommunity outreachRate of BCAnalysis of breast cancerRegistry dataBC communitiesOverall burdenCancer Center‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder
Myers A, Tan W, de Groot J, Westney O, Kamat A. ‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder. BJU International 2024, 134: 45-47. PMID: 38379218, DOI: 10.1111/bju.16302.Peer-Reviewed Original ResearchComparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database
Guram K, Huang J, Mouchati C, Abdallah N, Jani C, Navani V, Xie W, Zarif T, Adib E, Gebrael G, Agarwal N, Li H, Labaki C, Labban M, Morales J, Choueiri T, Heng D, Mittal A, Hansen A, Rose B, McKay R. Comparison of outcomes for Hispanic and non‐Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database. Cancer 2024, 130: 2003-2013. PMID: 38297953, DOI: 10.1002/cncr.35216.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaOverall survivalNHW patientsStatistically significant differenceSystemic therapyCell carcinomaHazard ratioAdvanced renal cell carcinomaMetastatic renal cell carcinomaCancer CenterFirst-line treatment failureMultivariate Cox regression analysisIMDC risk groupsKaplan-Meier methodSignificant differenceCox regression analysisCox regression hazard ratiosTertiary cancer centerAuthors investigated outcomesNon-Hispanic patientsMedian OSComparison of outcomesMetastatic sitesBone metastasesTreatment failureImpact of Financial Costs on Patients' Fertility Preservation Decisions: An Examination of Qualitative Data from Female Young Adults with Cancer and Oncology Providers
Dorfman C, Stalls J, Shelby R, Arthur S, Acharya K, Davidson B, Corbett C, Greenup R. Impact of Financial Costs on Patients' Fertility Preservation Decisions: An Examination of Qualitative Data from Female Young Adults with Cancer and Oncology Providers. Journal Of Adolescent And Young Adult Oncology 2024, 13: 502-513. PMID: 38294823, DOI: 10.1089/jayao.2023.0108.Peer-Reviewed Original ResearchFertility preservation decisionsFertility preservationImpact of financial costsFemale young adultsYoung adultsFamily building goalsHistory of cancerPreservation decisionsInsurance coverageOncology providersProviders expressed concernsCancer patientsComprehensive cancer centerReproductive ageCancer CenterNational Cancer Institute-designated comprehensive cancer centerCancer Institute-designated comprehensive cancer centerReproductive specialistsPatientsBuilding goalsCancerPrevalence and predictors of aspirin/NSAID use among patients with Lynch syndrome (LS).
Singhal S, Chertok Y, Osorio N, Chavez J, Riggs E, Daly M, Hall M. Prevalence and predictors of aspirin/NSAID use among patients with Lynch syndrome (LS). Journal Of Clinical Oncology 2024, 42: 19-19. DOI: 10.1200/jco.2024.42.3_suppl.19.Peer-Reviewed Original ResearchLynch syndromeAssociated with CPCP useLS patientsPatient advocacy websitesPatient-level factorsPersonal historyColonoscopy surveillanceCP benefitColorectal CAHereditary cancerPatients' perceptionsLifetime riskAdvocacy websitesMarital statusCP usersImpact uptakePrevention benefitsLS participantsPerceptions of CPE-surveyCancer CenterPrevention modalitiesNon-usersPerceived inconvenience
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply